This text is a result of machine translation.
Jiangsu Hengrui, Chinese Cancer Drugmaker Emerging from the Shadows
A flagship in the Chinese oncology market, Jiangsu Hengrui Medicine (600276:SH) was accused of corruption in sales. This was soon followed by good news – an approval of a Phase III clinical test. Will a bright future erase the black stain?
May 22, 2020 10:52 PM
Hydrogen energy industry policy: warm wind blows the industrial chain; listed companies accelerate to enter the new track
Declaration of the first affordable rental housing REITs
Beijing Pilots The DRG External Payment Mode
DRG refers to the diagnosis-related group used to classify the patient and set up a system to ensure the care provided is necessary. The National Healthcare Security Administration will pay the hospital a predetermined amount according to a patient’s DRG.
Jul 16, 2022 12:12 AM
Exclusive Interview: NAVEE GOLF Is Building a Smart Golf Ecosystem, Starting with Push Carts
Yesterday 05:04 PM
Chinese Embodied AI Company AI² Robotics: The Real Bottleneck in Embodied AI Is Scenarios, Not Just AI
Apr 14, 2026 11:25 AM
From 0 to 2.6 million units, Ecovacs Window Robot makes "first choice" the only answer.
Apr 10, 2026 07:00 PM